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Abstract 
Purpose: To evaluate the protective effects of grifolin against brain injury in an acute cerebral ischemia 
rat model. 
Methods: Rats were assigned to five groups: control, negative control, and grifolin (50, 100, and 200 
mg/kg, p.o.) treated groups, which received the drug for 2 weeks. All the animals were sacrificed at the 
end of the protocol, and tissue homogenates were prepared from isolated brain tissue. Glutathione 
peroxidase (GPX), superoxide dismutase (SOD), malondialdehyde (MDA), and nitric oxide (NO), as 
oxidative stress indicators, were determined for the tissue homogenates of the ischemic rats. 
Inflammatory mediators (cytokines and nuclear factor kappa B p65, NF κB), DNA damage, and ATP and 
caspase 3 levels in the tissue homogenates were also assessed. 
Results: Treatment with grifolin increased SOD and GPX significantly and decreased MDA and NO 
levels in tissue homogenates of the cerebral ischemic rats compared with those in the negative control 
group (p < 0.05). Treatment with grifolin also attenuated the altered levels of inflammatory mediators 
(cytokines and NF-κB), caspase 3, and ATP levels in the tissue homogenate of cerebral ischemic rats (p 
< 0.05). The results of comet assay on the tissue homogenate suggest that treatment with grifolin 
reduced or prevented damage. 
Conclusions: The results show that treatment with grifolin protects against neuronal damage in acute 
cerebral ischemic rats via its anti-inflammatory and anti-oxidant properties. 
 
Keywords: Neuroprotection, Cerebral ischemia, Brain injury, DNA, Grifolin, Anti-oxidant 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Stroke is a major cause of death worldwide [1]. 
The brain is a major organ and requires a large 
and constant blood supply to satisfy its metabolic 
demands. Thus, even a small alteration in blood 
flow to the brain results in neurological 
dysfunction and cerebral ischemia [2]. The 
pathogenesis of brain injury in cerebral ischemia 
involves enhanced apoptosis, inflammation, and 
redox imbalance [3]. It has also been reported 
that the condition worsens due to oxidative 
insults because they result in a decrease in the 
concentration of endogenous anti-oxidants and 
enhanced oxidative metabolic activity [4]. 
 
Previous reports have suggested that some 
“alternative” medicines, such as herbal extracts 
and natural products, show promising effects in 
the management of cerebral ischemia-induced 
Jing et al 
Trop J Pharm Res, June 2017; 16(6): 1300  
 
injuries. Extracts of various plants, such as garlic, 
Ginkgo biloba, and Nigella sativa, showed 
beneficial effects against cerebral injury in 
experimental rat models [5,6]. Grifolin is a 
phenolic compound isolated from the Albatrellus 
ovinus mushroom [7]. There are reports that 
grifolin possesses potent anti-inflammatory and 
anti-cancer activities [8,9]. One study reported 
that grifolin inhibited the production of nitric oxide 
(NO) in LPS-stimulated RAW 264.7 cells [10]. It 
also inhibited the release of histamine from mast 
cells [11]. Moreover, it has been shown to 
possess anti-atherosclerotic activity and has 
been used in the management of cardiovascular 
disease [12]. In this study, we investigated the 







Male albino Wistar rats (age: 8 weeks, weight: 
230–280 g) were used for pharmacological 
screening in this study. All the animals were 
housed with a 12-h light/dark cycle at 25 ± 2 °C 
and 60 ± 5 % humidity. Animals were fed a 
standard diet and water ad libitum. All 
experiments were approved by the Ethical 
Committee of The Second Hospital affiliated with 
Zhejiang University School of Medicine, China 
(approval no. TX136743), and the given study 
follows the guidelines of Association for the 
Assessment and Accreditation of Laboratory 
Animal Care International (AAALAC) for 




The Kunming Institute of Botany, China, provided 
the grifolin (> 99 % purity, HPLC grade). Other 
chemicals were from Sigma-Aldrich (St. Louis, 
MO, USA). 
 
Evaluation of toxicity 
 
An acute toxicity study for grifolin was conducted 
according to the OECD 423 guideline. Grifolin 
was administered at different doses (5, 50, 300, 
and 2000 mg/kg, p.o.) to the animals, which were 
observed closely for 2 weeks. All of the animals 
were observed for mortality and changes in 
behavior after 2 weeks of drug administration. It 
was found that grifolin at a dose of 2000 mg/kg 
was safe in the animals. 
  
Protocol design  
 
The animals were divided into five groups (n = 10 
each). The control group was sham-operated. In 
the negative control group, the ischemic group 
was ‘treated’ with vehicle alone. Grifolin-treated 
rats received 50, 100, or 200 mg/kg, p.o., for 2 
weeks. Then, ischemia was induced for 60 min 
and reperfusion was then allowed for a further 60 
min [14]. 
 
Induction of cerebral ischemia 
 
Animals were anesthetized with an injection of 
chloral hydrate (360 mg/kg, i.p.) and then 
subjected to ischemia-reperfusion. An incision 
was made in the neck to expose the carotid 
arteries. The exposed arteries were then 
clamped for 60 min to produce cerebral ischemia 
and then reperfusion was allowed to occur for 60 
min after unclamping the arteries. To avoid 
hypothermia, the animals were maintained at 37 
°C. 
 
Tissue homogenates  
 
All animals were sacrificed by cervical dislocation 
after reperfusion. The brain was isolated by 
opening the cranial cavity. Ice-cold phosphate 
buffer solution was used to homogenize the brain 
tissue (5 mL : 1 g). 
 
Evaluation of oxidative stress parameters 
 
The principle of the assay depends on the 
reaction of MDA with thiobarbituric acid in an 
acidic medium when incubated for 45 min at 95 
°C. The concentration of MDA was estimated in 
the brain tissue homogenate by observing the 
absorbance at 520 and 535 nm using a 
spectrometer. The concentration of MDA in the 
brain tissue was considered to indicate the level 
of lipid peroxidation. A reported method was 
used to determine nitric oxide (NO). Here, the 
level of NO was estimated by observing nitrate to 
nitrite reduction at 540 nm. A riboflavin-sensitized 
method was used to determine the activity of 
superoxide dismutase (SOD) in the tissue 
homogenate. Absorbance was observed for 4 
min at 460 nm. The method described by Paglia 
and Valentine was used for the determination of 
glutathione peroxidase (GPX) enzyme activity 
and the decrease in the optical density at a 
wavelength of 340 nm was considered to indicate 
the activity of the enzyme [14]. 
 
Determination of cytokines 
 
Concentrations of TNF-α and IL-10 in the tissue 
homogenates were determined using ELISAs. In 
the protocols, the absorbance was observed at 
450 nm for both cytokines [14]. 
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Evaluation of nuclear factor-κB p65 (NF-κB 
p65) 
 
An ELISA method was used to determine the 
NF-κB p65 in the tissue homogenate. A freeze-
thaw cycle was used to break the cell 
membranes and the mix was centrifuged (5000 × 
g, 5 min, 2 °C). The supernatant was then 
removed for the assay. The optical density was 
determined at 450 nm [15]. 
 
Determination of caspase-3 levels 
 
The level of caspase 3 was estimated using an 
ELISA kit. A microplate reader was used for the 
measurement of the final solution’s absorbance 
at 450 nm [15]. 
 
Assessment of ATP 
 
In the tissue homogenate, the level of ATP was 
determined using an ELISA. The optical density 
of the resulting solution was determined at 450 
nm [15]. 
 
Determination of DNA damage 
 
The comet assay was used to assess DNA 
damage. The tissue homogenate in PBS was 
stirred for 5 min. Then, the tissue homogenate 
was filtered and 100 µL of the cell suspension 
was mixed with agarose. The mixture was 
spread on an agarose pre-coated slide and DNA 
was unwound by placing it in an electrophoresis 
chamber (20 min, 180 mA, 25 V). Then, 0.4 M 
Tris-HCl buffer was used to wash the slides and 
they were stained with ethidium bromide solution. 
A fluorescence microscope was used to observe 
the DNA fragments on each slide. The Comet 5 
imaging software (Kinetic Imaging Ltd., UK) was 
used to estimate cellular DNA damage [15]. 
 
Statistical analysis  
 
Data are reported as mean ± SD (n = 10) and 
were analyzed using one-way ANOVA (with 
Dunnett’s post hoc test) using the GraphPad 
Prism software (ver. 3.0; San Diego, CA, 





The effects of grifolin on the parameters of 
oxidative stress are shown in Table 1. It shows 
that treatment with grifolin decreased the levels 
of MDA and NO significantly (p < 0.05 and 
p < 0.01, respectively) in the tissue homogenate 
of ischemic rats versus the negative control 
group. Moreover, the activities of GPX and SOD 
were enhanced significantly in the tissue 
homogenates from the grifolin-treated groups 
compared with those in the negative control 
group. The effect of grifolin on the parameters of 
oxidative stress was dose-dependent. 
 
Effect of grifolin on levels of cytokines 
 
There was a significant decrease in IL-10 and an 
increase TNF-α in the tissue homogenates of 
ischemic rats. Treatment with grifolin significantly 
enhanced the IL-10 and decreased the TNF-α 
levels in tissue homogenate versus those in the 
negative control group, in a dose-dependent 
manner (Figure 1). 
 
Effect of grifolin on NF-κB p65 
 
The effects of grifolin on the level of NF-κB p65 
in the tissue homogenate of the ischemic rats are 
shown in Figure 2. There was a significant (p < 
0.01) decrease in the level of NF-κB p65 in 
grifolin-treated ischemic rats versus that in the 
negative control group. 
 
Effect of grifolin on caspase-3 
 
The level of caspase 3 was increased 
significantly in the tissue homogenate of 
ischemic rats in the negative control group 
versus that in the control group. Treatment with 
grifolin decreased the level of caspase 3 
significantly (p < 0.01) in ischemic rats compared 
with that in the negative control group, in a dose-
dependent manner (Figure 3). 
 
Table 1: Effect of grifolin on oxidative stress in tissue homogenates 
 
Group MDA 
(µM/100 mg of 
wet tissue) 
NO 
(mM/100 mg of 
wet tissue) 
SOD 
(U/100 mg of wet 
tissue) 
GPX 
(U/ 100 mg of 
wet tissue) 
Control 2.63±0.36 8.87±0.75 2.95±0.32 182.4±11.2 
Negative control 7.95±0.58## 19.56±1.5## 0.69±0.05## 83.4±8.1## 
Grifolin (50 mg/kg) 5.87±0.25* 15.4±0.61* 1.1±0.12** 99.5±7.5** 
Grifolin (100 mg/kg) 4.15±0.11** 12.9±0.83** 1.85±0.28** 137.2±10.1** 
Grifolin (200 mg/kg) 3.26±0.15** 10.3±0.47** 2.37±0.41** 159.8±13.4** 
Data are means ± SDs (n = 10). ##p < 0.01, vs. control, * p < 0.05, ** p < 0.01, vs. negative control 
Jing et al 
Trop J Pharm Res, June 2017; 16(6): 1302  
 
  
Figure 1: Effect of grifolin on cytokines in the tissue homogenate. Data are presented as means ± 
SDs (n = 10). ## p < 0.01, vs. control, * p < 0.05, ** p < 0.01, vs. the negative control 
 
 
Figure 2: Effects of grifolin on the level of NF-κB p65 in tissue homogenate. Data are presented as 
means ± SDs (n = 10). ## p < 0.01, vs. control, * p < 0.05, ** p < 0.01, vs. the negative control 
 
 
Figure 3: Effect of grifolin on caspase 3 in tissue homogenates. Data are presented as means ± SDs (n = 10). ## 
p < 0.01, vs. control, *p < 0.05, **p < 0.01, vs. the negative control 
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Figure 4: Effect of grifolin on ATP levels in tissue homogenates. Data are presented as means ± SDs (n = 10). ## 
p < 0.01, vs. control, * p < 0.05, ** p < 0.01, vs. negative control 
 
Effect of grifolin on ATP levels 
 
Ischemia resulted in a decrease in the brain ATP 
level in the negative control group compared with 
that in the control group (Figure 4). There was a 
significant increase (p < 0.05, p < 0.01) in the 
brain ATP level in the grifolin-treated groups 
versus that in the negative control group in a 
dose-dependent manner. 
 
Effect of grifolin on DNA damage 
 
The comet assay was used to estimate the 
effects of grifolin on DNA damage in tissue 
homogenate (Figure 5). DNA damage was 
evaluated by estimating the tail moment, DNA 
tail, the length of the tail, and the percentage of 
tailed and untailed cells with extracted cellular 
DNA. There were significant increases (p < 0.01) 
in the percentage of untailed cells and a 
decrease in the percentage of tailed cells in the 
grifolin-treated groups versus the negative 
control group. Additionally, treatment with grifolin 
significantly decreased the tail moment, DNA 
tailing, and tail length in the ischemic rats versus 




Neuronal cell degeneration in cerebral ischemia 
results from enhanced levels of cytokines and 
oxidative stress. Ischemia, like other pathological 
conditions, disturbs homeostasis. In this study, 
we evaluated the effects of grifolin in cerebral 
ischemic conditions and also suggest its possible 
mechanism of action. 
 
There are several reports claiming that 
ischemic/reperfusion conditions enhance 
oxidative stress, thereby damaging cellular 
proteins and nucleic acids [16]. The result of 
another study showed that grifolin reduced 
oxidative stress, attenuating the changes in 
various parameters reflecting it. Ischemia has 
also been reported to increase the production of 
inflammatory mediators [17]. The present study 
suggested that grifolin significantly decreased 
inflammatory mediators in ischemic rats versus 
those in the negative control group. 
 
Apoptosis is activated by increased caspase 3 
activity [18]. Apoptosis in a tissue also disturbs 
mitochondrial function, such as ATP production. 
Treatment with grifolin decreased the activity of 
caspase 3 and the level of ATP in the tissue 
homogenate of ischemic rats versus those in the 
negative control group. This resulted in 
protection from DNA damage in the grifolin-
treated ischemic rats compared with the status in 




From the present study, we conclude that grifolin 
protects neurons in acute cerebral ischemia. 
Specifically, it inhibits the process of apoptosis 
through its anti-inflammatory and anti-oxidant 
properties. 
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Figure 5: Effects of grifolin on DNA damage, as determined by the comet assay. Data are presented as means ± 
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